Researching bladder afferents-determining the effects of β(3) -adrenergic receptor agonists and botulinum toxin type-A.
about
Mirabegron: a review of recent data and its prospects in the management of overactive bladderNew therapeutic strategies for the treatment of male lower urinary tract symptomsClinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndromeUrothelial signaling.Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.Do the urinary bladder and large bowel interact, in sickness or in health? ICI-RS 2011.Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladderOrganization of the neural switching circuitry underlying reflex micturitionA functional analysis of the influence of β3-adrenoceptors on the rat micturition cycleMechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011.Botulinum toxin injection for lower urinary tract dysfunction.Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "overactive bladder".Genitourinary and gastrointestinal co-morbidities in children: The role of neural circuits in regulation of visceral function.Expression of β-Adrenoceptor Subtypes in Urothelium, Interstitial Cells and Detrusor of the Human Urinary Bladder.Electrophysiological properties of lumbosacral primary afferent neurons innervating urothelial and non-urothelial layers of mouse urinary bladder.Urothelial ATP exocytosis: regulation of bladder compliance in the urine storage phase.
P2860
Q24617239-D364C418-499D-48E3-A512-2F0DEAEE9851Q26746138-8AE59CC5-2AF1-43C2-B2FB-C81C81036E5BQ26783536-9181E110-5652-46AA-8CA2-F29841272EBEQ30440958-3C52A663-0E6E-4A47-81F8-7DD61B358D86Q34405906-6695A73C-AA16-48CF-8D5E-9E9A219A2806Q35842916-E07A1B70-F3C7-4DB6-AEEE-556FCBDABEB0Q36401506-EA9109DF-5E2B-44AF-B461-4CCF3DC2F7F9Q36573132-AF5CD7C0-A072-48AD-A112-EB8EC3F71CFBQ37031403-3D78962F-094E-49B0-A2F9-FB96E87EBD2DQ37252037-84EC7321-9DB8-49B8-8C1B-A21F3E405616Q37978568-6E45954A-8FE7-43C2-91EB-9862DAD0AF3AQ38008697-D96093F7-BC2A-4CE9-826B-84B8D0628392Q38031284-A3997028-C1B0-4437-B18D-0A75CA473937Q38231747-C81661BF-5811-4002-912F-379613E5E0FEQ39229887-218F97CF-5262-4B5D-AE75-C18C7D1D56B2Q40215763-E5C7B243-932F-4117-8AE6-6AF6AD4843B9Q41635805-9F968435-DA09-4DC3-A731-A4789151CB68Q42422183-BF0BA672-763B-4FA5-9F53-4BE5B01F59AE
P2860
Researching bladder afferents-determining the effects of β(3) -adrenergic receptor agonists and botulinum toxin type-A.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Researching bladder afferents-determining the effects of β
@nl
Researching bladder afferents- ...... ts and botulinum toxin type-A.
@en
type
label
Researching bladder afferents-determining the effects of β
@nl
Researching bladder afferents- ...... ts and botulinum toxin type-A.
@en
prefLabel
Researching bladder afferents-determining the effects of β
@nl
Researching bladder afferents- ...... ts and botulinum toxin type-A.
@en
P2093
P2860
P356
P1476
Researching bladder afferents- ...... sts and botulinum toxin type-A
@en
P2093
Anthony Kanai
Christopher Fry
Irina Zabbarova
Karl-Erik Andersson
Stefan De Wachter
P2860
P304
P356
10.1002/NAU.21102
P577
2011-06-01T00:00:00Z